The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of January 31, 2018:

• 35 negotiations are currently underway with 2 new files added since the last update of December 31, 2017:
  • Spinraza (nusinersen): Used to treat 5q Spinal Muscular Atrophy
  • Victoza (liraglutide): Used to treat type 2 diabetes mellitus
• 200 joint negotiations have been completed with 3 new files added since the last update of December 31, 2017:
  • Gazyva (obinutuzumab): Used to treat follicular lymphoma
  • Narcan (naloxone hydrochloride): Used to treat opiod overdose
  • Strensiq (asfotase alfa): Used to treat pediatric-onset hypophosphatasia
• 57 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update of December 31, 2017.
• 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with no new files added since the last update of December 31, 2017.

For more information, please consult the pCPA’s website.